Conversion efficiency and green power of compact reverse-proton-exchanged MgO:LiNbO3 waveguides

R. Roussev,V. Bhagavatula,U. Goers

DOI: https://doi.org/10.1364/CLEO_SI.2013.CW1B.4

2013-06-09

Abstract:A sub-cm-long reverse-proton-exchanged waveguide with record normalized efficiency showed 44.2% peak internal continuous-wave single-pass conversion, 196-mW peak green, and overall conversion peaking at 30%, being above 25% for green outputs above 80 mW.

What problem does this paper attempt to address?

Soft-start circuitry for DC motor

Zong-Han Lu,Fuyan Sun

DOI: https://doi.org/10.1109/ICECENG.2011.6057599

2011-10-24

Abstract:This paper presents a soft-start circuit using the pulse-width-modulation (PWM) method. The motor is controlled by the dc chopper associated with a low-cost PWM chip TL494. The design criteria are stated. The motor HC385MG is tested in experiment. The results illustrate that the circuit effectively reduces the inrush current at start-up moment. The circuit also provides the speed adjustment and can be further implemented with the speed regulation and the over-current protection.
AB085. Systematic Review and Meta-Analysis of Phosphodiesterase Type 5 Inhibitors for the Treatment of Female Sexual Dysfunction

Liang Gao,Lu Yang,Shengqiang Qian,Tao Li,Ping Han,Jiuhong Yuan

DOI: https://doi.org/10.21037/tau.2016.s085

2015-01-01

Abstract:Objective To obtain systematic and comprehensive evidence regarding the benefits and safety of PDE5i compared to those of placebo. Methods All randomized controlled trials (RCTs) reporting on the effectiveness of PDE5i in FSD were identified through comprehensive searches of PubMed, the Cochrane Library and Embase, and a meta-analysis and systematic review of these studies were conducted. Results Fourteen studies were included for meta-analysis. Because RCTs included in our study adopted different questionnaires for the measurement of sexual function, most of the data had to be separated rather than pooling the results. Summarizing the results of each comparison, we found that the use of PDE5i resulted in a significant improvement in sexual functioning compared with placebo in most studies, except for a few sporadic negative results. However, pooled data for adverse events showed significantly higher rates of headache, flushing, and vision changes in PDE5i treatment group [risk ratio (RR) 2.59, 95%95% confidence interval (CI), 1.93–3.47, P<0.00001; RR 5.74, 95% CI, 3.60–9.14, P<0.00001; and RR 4.64, 95% CI, 2.16–9.98, P<0.0001, respectively]. However, no one reported the need of any additional therapy for these adverse events. Conclusions Our results indicate that PDE5i would be effective for female sexual dysfunction. Though there were significantly higher rates of adverse events, use of PDE5i was still relatively safe. More well-designed, double-blind, crossover RCTs reporting results from standardized questionnaires should be conducted to accurately solve this issue.
Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Yatan Pal Singh Balhara,Siddharth Sarkar,Rishab Gupta

DOI: https://doi.org/10.4103/2230-8210.159023

Abstract:Background and aims: Patients with diabetes mellitus frequently experience erectile dysfunction. This systematic review and meta-analysis were conducted to find efficacy and tolerability of phosphodiesterase 5 (PDE5) inhibitors in patients with diabetes mellitus experiencing erectile dysfunction. Methodology: Electronic searches were carried out to identify English language peer-reviewed randomized controlled trials (RCTs), which reported clinical efficacy of any PDE5 inhibitor in patients with diabetes mellitus having erectile dysfunction. Effect sizes were computed using Cohen's d, and I(2) -test was used to assess heterogeneity. Pooled mean effect sizes were computed using random-effects model. Number needed to treat (NNT), and the adverse event rates were computed. Results: The systematic review included a total of 17 studies yielding 25 comparisons. Three studies were open RCTs while others were double-blind RCTs. The pooled mean effect size of any PDE5 inhibitor over placebo was 0.926 (95% confidence intervals [CI]: 0.864-0.987; I(2) =26.3). The pooled mean effect size for sildenafil was 1.198 (CI: 1.039-1.357; I(2) =0), for tadalafil was 0.910 (CI: 0.838-0.981; I(2) =33.6), and for vardenafil was 0.678 (CI: 0.627-0.729; I(2) =0). In pooled analysis, the NNT for sildenafil, tadalafil, vardenafil and any PDE5 inhibitor was 2.4, 2.6, 4.1 and 3.0 respectively. The most common side effects were headache, flushing, and nasal congestion. Conclusions: PDE5 inhibitors are effective and safe medications for the treatment of sexual dysfunction in patients with diabetes mellitus experiencing erectile dysfunction.
Cell-surface accumulation of flock house virus-derived peptide leads to efficient internalization via macropinocytosis.

I. Nakase,Hisaaki Hirose,Gen Tanaka,A. Tadokoro,Sachiko Kobayashi,T. Takeuchi,S. Futaki

DOI: https://doi.org/10.1038/mt.2009.192

IF: 12.91

2009-11-01

Molecular Therapy

Abstract:
Efficacy of Selective Inhibitors of Phosphodiesterase-5 (PDE-5) for Erectile Dysfunction:A Clinical Evaluation

ZHOU Xin,ZHAI Suo-di

DOI: https://doi.org/10.14009/j.issn.1672-2124.2009.06.009

2009-01-01

Abstract:OBJECTIVE: Selective PDE-5 inhibitors play an important role in the treatment of erectile dysfunction.Sildenafil,vardenafil and tadenafil are widely used PDE-5 inhibitors in clinical treatment of erectile dysfunction.However,their differences in efficacy and safety have become the focus of attention.This paper summarized and evaluated the efficacy and safety of the above 3 drugs.METHODS: The clinical evidences on the study of the action mechanism,pharmacokinetics,the efficacy,onset time and duration of the action,effective rate and related adverse events of the 3 drugs were collected and the pertinent literature both at home and abroad was reviewed.RESULTS & CONCLUSION: All the three drugs are highly effective yet no reliable evidence is available to prove which one is superior to the others,which still requires more randomized controlled studies to confirm.
Proceedings of the 26th Annual International Conference on Design of Communication, SIGDOC 2008, Lisbon, Portugal, September 22-24, 2008

Henrique O'Neill,M. Aparicio,C. Costa,A. Protopsaltis

Abstract:
Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction

R Andrew Moore,Sheena Derry,Henry J McQuay

DOI: https://doi.org/10.1186/1471-2490-5-18

2005-12-14

Abstract:Background: There are no randomised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting. Valid indirect comparisons with a common comparator must examine equivalent doses, similar duration, similar populations, with the same outcomes reported in the same way. Methods: Published randomised, double-blind trials of oral PDE-5 inhibitors for erectile dysfunction were sought from reference lists in previous reviews and electronic searching. Analyses of efficacy and harm were carried out for each treatment, and results compared where there was a common comparator and consistency of outcome reporting, using equivalent doses. Results: Analysis was limited by differential reporting of outcomes. Sildenafil trials were clinically and geographically more diverse. Tadalafil and vardenafil trials tended to use enriched enrollment. Using all trials, the three interventions were similar for consistently reported efficacy outcomes. Rates of successful intercourse for sildenafil, tadalafil and vardenafil were 65%, 62%, and 59%, with placebo rates of 23-28%. The rates of improved erections were 76%, 75% and 71%, respectively, with placebo rates of 22-24%, and NNTs of 1.9 or 2.0. Reporting of withdrawals was less consistent, but all-cause withdrawals for sildenafil, tadalafil and vardenafil were 8% 13% and 20%. All three drugs were well tolerated, with headache being the most commonly reported event at 13-17%. There were few serious adverse events. Conclusion: There were differences between trials in outcomes reported, limiting comparisons, and the most useful outcomes were not reported. For common outcomes there was similar efficacy between PDE-5 inhibitors.
Integrating Systematic Chronic Care for Diabetes into an Academic General Internal Medicine Resident-Faculty Practice

A. Dipiero,D. Dorr,C. Kelso,J. Bowen

DOI: https://doi.org/10.1007/s11606-008-0751-5

IF: 5.7

2008-08-28

Journal of General Internal Medicine

Abstract:
Changes in left ventricular function after mitral valve repair for severe organic mitral regurgitation.

T. Witkowski,James D. Thomas,V. Delgado,E. V. van Rijnsoever,A. Ng,U. Hoke,S. Ewe,D. Auger,K. Yiu,E. Holman,R. Klautz,M. Schalij,Jeroen J. Bax,N. Marsan

DOI: https://doi.org/10.1016/j.athoracsur.2011.11.034

2012-03-01

Abstract:
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis

Chengquan Ma,Jianzhong Zhang,Zhonglin Cai,Jian Xiong,Hongjun Li

DOI: https://doi.org/10.1155/2020/1419520

2020-03-26

Abstract:Purpose: The purpose of this study was to compare the relative safety and efficacy of different types of phosphodiesterase type 5 inhibitors (PDE5-Is) with tamsulosin for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostate hyperplasia (BPH) (BPH-LUTS) with or without erectile dysfunction (ED). Methods: We use the Stata version 13.0 to conduct the network meta-analysis (NMA) with a random effects model of the Bayesian framework. The International Prostate Symptom Score (IPSS), Maximum Urinary Flow Fate (Q max), International Index of Erectile Function (IIEF), and their credible intervals (CI) were used to compare the efficacy and safety of every medical intervention, including sildenafil plus tamsulosin, tadalafil plus tamsulosin, and vardenafil plus tamsulosin. Results: Seven RCTs including 531 participants with seven interventions were analyzed. The results of NMA SUCRA showed that compared with different doses or types of PDE5-Is combined with tamsulosin (0.4 mg qd), the sildenafil (25 mg qd) combined with tamsulosin (0.4 mg qd) group had the greatest probabilities of being the best in the achievement of improving IIEF. The sildenafil (25 mg 4 days per week) combined with tamsulosin (0.4 mg qd) group had the greatest probabilities of being the best in the achievement of improving Q max, whereas sildenafil (25 mg qd) combined with tamsulosin (0.4 mg qd) ranked the best for the safety outcomes. Conclusions: This meta-analysis indicates that sildenafil combined with tamsulosin is the best effective and tolerated treatment option for BPH-LUTS with or without ED. Further RCTs are strongly required to provide more direct evidence.
[Cardiopulmonary exercise testing: the exercise stress test of the future?].

R. Belardinelli

2005-02-01

Abstract:Scientific evidence is mounting that cardiopulmonary exercise testing (CPET) offers different potential clinical applications in cardiology. In comparison with traditional ECG stress testing, CPET provides more accurate diagnostic information and prognostic insights as well, in particular in patients with chronic heart failure and primary pulmonary hypertension. The barriers that actually limit the diffusion of CPET among cardiologists are primarily "cultural", because modern ergospirometric tools are easy to use, and the time required for a CPET is not dissimilar from that of a standard ECG stress test. At present, time seems to be ripe for considering CPET as the new exercise stress test in cardiology.
The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

Eugenio Ventimiglia,Paolo Capogrosso,Francesco Montorsi,Andrea Salonia

DOI: https://doi.org/10.1517/14740338.2016.1131818

Abstract:Introduction: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related adverse events. Areas covered: This paper reviews the safety profile of currently available PDE5Is, comparing them in a broad spectrum ED population and outlining a number of real-life aspects of importance in the real-life everyday clinical setting. Expert opinion: Guidelines unanimously agree in considering PDE5Is as first line treatments for ED when well-tolerated and not contraindicated. Despite the fact that no high-grade evidence comparing the efficacy and the safety for PDE5Is is currently available, published data seem to suggest that there are no major differences in their safety proﬁles. Moreover, although oral PDE5Is were shown to cause more AEs than placebo, they were generally mild and well tolerated.
Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors

Jeong Hee Hong,Young Suk Kwon,Isaac Yi Kim

DOI: https://doi.org/10.1080/17425255.2017.1244265

2016-10-21

Abstract:INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5Is) are the first-line drugs in the management of erectile dysfunction (ED). However, over the past two decades tremendous efforts have been made to identify new clinical uses of PDE5Is beyond their roles in ED. Areas covered: Basic science articles, clinical trials, reviews, and meta-analysis published between 1996 and 2015 were searched using MEDLINE (PubMed interface) to collect the most relevant and impactful studies from our perspectives as practicing urologists. This review mainly focuses on the level one evidence-based clinical efficacy and drug-related toxicity of oral PDE5Is. In addition, drug discovery, pharmacokinetics and pharmacodynamics, potential use in other diseases, and future directions are discussed. Expert opinion: On-demand PED5Is for the treatment of ED has shifted toward chronic administration in a broad spectrum of conditions that are thought to be associated with endovascular health. Several studies have shown that PDE5Is may play a cardioprotective or neuroprotective role. Further studies are under way to verify beneficial effects of PDE5I in non-urological conditions.

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials

Wan Du,Jing Li,Ning Fan,Panfeng Shang,Zhiping Wang,Hui Ding

DOI: https://doi.org/10.3109/13685538.2013.858114

Abstract:Aim: To systematically review evidence on the efficacy and safety of mirodenafil treatment in erectile dysfunction (ED) from randomised controlled trials. Methods: We searched PubMed, Embase and the Cochrane Library database up to March 2013. Two authors independently assessed study quality and extracted data. All data were analyzed using RevMan 5.0. Outcome measures assessed were the International Index of Erectile Function (IIEF), erectile function domain (EFD) score (primary), the Sexual Encounter Profile questions 2 and 3, and the response to the Global Assessment Questionnaire and adverse effects (secondary). Results: A total of 374 participants from three randomized controlled trials were identified in this meta-analysis. After 12 weeks treatment, mirodenafil was found to be more effective than placebo, and tolerability was good. The pooled results showed that the IIEF EFD score for 100 mg mirodenafil group was higher than placebo group (MD = 8.13, 95%CI: 6.64-9.61, p < 0.00001) and the mirodenafil group was also higher than placebo group in the changes from baseline for the IIEF EFD score (MD = 7.32, 95%CI: 5.56-9.07, p < 0.00001), respectively. The most common drug-related adverse events were flushing and headache (mirodenafil versus placebo: 15.8% versus 3.2%, 3.1% versus 0%; respectively). Conclusion: This meta-analysis suggested that mirodenafil is effective and well-tolerated therapy for ED.
Analysis of bus collision and non-collision incidents using transit ITS and other archived operations data.

J. Strathman,Paul Wachana,S. Callas

DOI: https://doi.org/10.1016/j.jsr.2010.02.003

IF: 4.264

2010-04-01

Journal of Safety Research

Abstract:
PDE5 inhibitors: considerations for preference and long-term adherence

W B Smith 2nd,I R McCaslin,A Gokce,S H Mandava,L Trost,W J Hellstrom

DOI: https://doi.org/10.1111/ijcp.12074

Abstract:Introduction: Erectile dysfunction (ED) is a highly prevalent condition affecting nearly one in five men worldwide. The advent of phosphodiesterase type 5 inhibitors (PDE5i) has revolutionised the ED treatment landscape and provided effective, minimally invasive therapies to restore male sexual function. Materials and methods: A pubmed search was performed of all English language articles from 1996 to present reviewing PDE5i, including pharmacokinetics, efficacy profiles and comparisons, where available. Results: Currently available PDE5i in the United States include sildenafil, vardenafil, tadalafil and avanafil, each of which has unique side effect, pharmacokinetic and outcome profiles. Sildenafil is associated with increased rate of visual changes, vardenafil with QT prolongation and tadalafil with lower back pain. Avanafil and vardenafil orodispersible tablet rapidly achieve peak plasma concentration, which results in faster onset of action, whereas tadalafil exhibits the longest half-life. First time response to PDE5i is approximately 60-70%, with no significant differences in efficacy noted among therapies. The literature does not clearly demonstrate a preference for one drug. High-treatment success rates (89%) were reported when patients were prescribed all available PDE5i. Daily dosing with tadalafil is associated with improved erectile function (EF) over time. Finally, novel modes of patient-provider interaction, including internet-based education, communication and prescribing, may also improve long-term adherence. Conclusions: PDE5i represent first line therapy for ED with excellent overall efficacy and satisfactory side effect profiles. Enhanced communciation, coupled with increased knowledge of drug characteristics, comparative treatment regimens and optimal prescribing patterns, offer compelling tools to improve long-term treatment success.
Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis

Alexander Tsertsvadze,Howard A. Fink,Fatemeh Yazdi,Roderick MacDonald,Anthony J. Bella,Mohammed T. Ansari,Chantelle Garritty,Karla Soares-Weiser,Raymond Daniel,Margaret Sampson,Steven Fox,David Moher,Timothy J. Wilt

DOI: https://doi.org/10.7326/0003-4819-151-9-200911030-00150

IF: 39.2

2009-11-03

Annals of Internal Medicine

Abstract:BACKGROUND: Erectile dysfunction (ED) is a common male sexual disorder. The relative benefits and harms of pharmacologic therapies for ED, as well as the value of hormonal testing in men with ED, are uncertain.PURPOSE: To evaluate the efficacy and harms of oral phosphodiesterase-5 (PDE-5) inhibitors and hormonal treatments for ED and assess the effect of measuring serum hormone levels on treatment outcomes for ED.DATA SOURCES: English-language studies from MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, PsycINFO, AMED, and SCOPUS through April 2009. Trial reference lists also were scanned.STUDY SELECTION: Randomized, controlled trials (RCTs) of oral PDE-5 inhibitors and hormonal treatment for ED, and observational studies reporting measurement of serum hormone levels, prevalence of hormonal abnormalities, or both in men with ED.DATA EXTRACTION: Two independent reviewers abstracted data on study, participant, and treatment characteristics; efficacy and harms outcomes; and prevalence of hormonal abnormalities.DATA SYNTHESIS: Data, primarily from short-term trials (<or=12 weeks), indicate that PDE-5 inhibitors were more effective than placebo in improving sexual intercourse success (69.0% vs. 35.0%). The proportion of men with improved erections was significantly greater among those treated with PDE-5 inhibitors (range, 67.0% to 89.0%) than with placebo (range, 27.0% to 35.0%). The PDE-5 inhibitors were associated with increased risk for any adverse events compared with placebo (for example, relative risk with sildenafil, 1.72 [95% CI, 1.53 to 1.93]). In 4 head-to-head RCTs comparing sildenafil, vardenafil, and tadalafil, improvement of ED and adverse events did not differ among treatments. Results from 15 RCTs evaluating hormonal treatment of ED were inconsistent on whether treatment improved outcomes. Evidence was insufficient regarding whether men with ED had a higher prevalence of hypogonadism than men without ED.LIMITATIONS: Many RCTs were of low methodological and reporting quality, particularly those involving hormonal treatments or directly comparing different PDE-5 inhibitors. Most RCTs provided only short-term efficacy and harms data.CONCLUSION: Oral PDE-5 inhibitors improved erectile functioning and had similar efficacy and safety profiles. Results on the efficacy of hormonal treatments and the value of hormone testing in men with ED were inconclusive.PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

medicine, general & internal
Energetics of Large Fullerenes: Balls, Tubes, and Capsules

G. Adams,O. Sankey,J. B. Page,M. O'Keeffe,David Alan Drabold

DOI: https://doi.org/10.1126/science.256.5065.1792

IF: 56.9

1992-06-26

Science

Abstract:First-principles calculations were performed to compare the energies of 29 different fullerene structures, with mass number from 60 to 240, and of eight nonhelical graphite tubes of different radii. A quantity called the planarity, which indicates the completeness of the π-bonding, is the single most important parameter determining the energetics of these structures. Empirical equations were constructed for the energies of nonhelical tubes and for those fullerene structures that may be described as balls or capsules. For a given mass number, bail-shaped fullerenes are energetically favored over capsular (tube-like) fullerenes.
A morphological and immunohistochemical study of 25 cases of so‐called sclerosing haemangioma of the lung

A. Leong,K. Chan,H.S.K. Seneviratne

DOI: https://doi.org/10.1111/j.1365-2559.1995.tb00020.x

1995-08-01

Histopathology

Abstract:The so‐called sclerosing haemangioma of the lung is an uncommon tumour with predilection for Chinese women. Twenty‐five cases showed a predominantly solid/cellular pattern in three, a haemorrhagic/angiomatoid pattern in three, a papillary pattern in one, a sclerotic pattern in one, and in seventeen, a mixed pattern was observed. Immunostaining revealed the expression of epithelial membrane antigen, vimentin (V9), and CD68 (KP1) in all tumours, cytokeratin in 23 (Cam 5.2 and MNF116), S‐100 protein in 22 and alpha‐smooth muscle actin in 23 tumours. All tumours were negative for surfactant, factor VIII‐related antigen, CD34 and MAC387. There was strong labelling for progesterone receptor protein in 20 tumours, and oestrogen receptor protein was weakly stainable in 13 tumours. The histogenesis of sclerosing haemangioma of the lung is controversial and origin from pneumocyte, histiocyte, mesothelial, endothelial and Clara cell has been suggested. Our immunohistochemical findings, in the largest series studied to date, indicated a cytokeratin+, vimentin+, epithelial membrane antigen+, alpha‐smooth muscle actin+, CD68+, oestrogen+, progesterone+, phenotype, confirming an epithelial lineage but which does not clearly correspond to any recognized cell in the respiratory system. The distinct expression of progesterone and oestrogen receptor proteins correlates with the predilection of this tumour for women.
Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments

Zachary Melchiode,Tivoli Nguyen,Omar Dawood,Graham A Bobo,Wayne J G Hellstrom

DOI: https://doi.org/10.1080/13543784.2023.2242768

Abstract:Introduction: Erectile dysfunction (ED) is a condition that affects millions of men worldwide and is characterized by the inability to achieve or maintain an erection for satisfactory sexual performance. There are numerous treatment options for ED, including medications, mechanical assist devices, and surgical management; however, first-line treatment is usually a phosphodiesterase 5 (PDE5) inhibitor. There is a growing interest in developing novel, efficacious PDE5 inhibitors that provide better quality, safety, and tolerability profiles with less adverse effects. Our review of udenafil, mirodenafil, youkenafil, lodenafil, and SLx-2101 analyzes the safety, efficacy, and pharmacokinetic properties of these new ED drugs. Areas covered: Clinical trials demonstrated improved scores in questionnaires, such as the International Index of Erectile Function and Sexual Encounter Profile, for udenafil, mirodenafil, and lodenafil, while youkenafil and SLx-2101 revealed enhanced safety and tolerability in early pharmacokinetic studies. Expert opinion: It is our opinion that more robust clinical trials are required before these medications can be made available in the United States. Additionally, the field of urology may benefit from pursuing other avenues of pharmacotherapy, such as injections, tablets with a different mechanism of action, or stem cell therapy, to restore the integrity of the endothelium within the penis.

Conversion efficiency and green power of compact reverse-proton-exchanged MgO:LiNbO3 waveguides

Soft-start circuitry for DC motor

AB085. Systematic Review and Meta-Analysis of Phosphodiesterase Type 5 Inhibitors for the Treatment of Female Sexual Dysfunction

Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Cell-surface accumulation of flock house virus-derived peptide leads to efficient internalization via macropinocytosis.

Efficacy of Selective Inhibitors of Phosphodiesterase-5 (PDE-5) for Erectile Dysfunction:A Clinical Evaluation

Proceedings of the 26th Annual International Conference on Design of Communication, SIGDOC 2008, Lisbon, Portugal, September 22-24, 2008

Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction

Integrating Systematic Chronic Care for Diabetes into an Academic General Internal Medicine Resident-Faculty Practice

Changes in left ventricular function after mitral valve repair for severe organic mitral regurgitation.

Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis

[Cardiopulmonary exercise testing: the exercise stress test of the future?].

The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors

Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials

Analysis of bus collision and non-collision incidents using transit ITS and other archived operations data.

PDE5 inhibitors: considerations for preference and long-term adherence

Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis

Energetics of Large Fullerenes: Balls, Tubes, and Capsules

A morphological and immunohistochemical study of 25 cases of so‐called sclerosing haemangioma of the lung

Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments